| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Trial |
The pulmonary and systemic availability of budesonide after inhalation from a dry powder inhaler, Turbuhaler, and from a pressurized metered-dose inhaler (P-MDI) were compared in healthy volunteers. Two different methods were used to assess pulmonary availability: 1) calculated from the systemic availability corrected for an oral availability of 13% (n = 24); and 2) after blocking of gastrointestinal absorption by administration of a charcoal suspension (n = 13). An intravenous infusion of budesonide was used as a reference. The systemic availability of budesonide, calculated as a geometric mean and expressed as percentage of the metered dose, was 38% for Turbuhaler and 26% for P-MDI. The pulmonary availability, calculated using the first method, was 32% and 15% for Turbuhaler and P-MDI, respectively; and, using the second method, 32% and 18%, respectively. The results of the present study indicate that administration of budesonide via Turbuhaler gives rise to a lung deposition which is approximately twice that of a P-MDI, with less variability, but that systemic availability is only increased by approximately 50%. Thus, the present data suggest that by administrating budesonide via Turbuhaler, instead of a P-MDI, the same degree of asthma control can be achieved with a lower dose, which, in turn, reduces the risk of undesired systemic effects.
This article has been cited by other articles:
|
|
 |
|
  R. Hermann, W. Siegmund, T. Giessmann, K. Westphal, A. Weinbrenner, B. Hauns, F. Reutter, G. Lahu, K. Zech, and T. D. Bethke The Oral, Once-Daily Phosphodiesterase 4 Inhibitor Roflumilast Lacks Relevant Pharmacokinetic Interactions With Inhaled Budesonide J. Clin. Pharmacol., August 1, 2007; 47(8): 1005 - 1013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Derendorf, R. Nave, A. Drollmann, F. Cerasoli, and W. Wurst Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J., November 1, 2006; 28(5): 1042 - 1050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cerasoli Jr Developing the Ideal Inhaled Corticosteroid Chest, July 1, 2006; 130(1_suppl): 54S - 64S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Inhalation devices Can. Med. Assoc. J., September 13, 2005; 173(6_suppl): S39 - S45. [Full Text] [PDF]
|
|
|
|
|
|
R. Petersen, L. Agertoft, and S. Pedersen Treatment of exercise-induced asthma with beclomethasone dipropionate in children with asthma Eur. Respir. J., December 1, 2004; 24(6): 932 - 937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Winkler, G. Hochhaus, and H. Derendorf How the Lung Handles Drugs: Pharmacokinetics and Pharmacodynamics of Inhaled Corticosteroids Proceedings of the ATS, December 1, 2004; 1(4): 356 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hochhaus New Developments in Corticosteroids Proceedings of the ATS, November 1, 2004; 1(3): 269 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Phillips, J Oborne, S Lewis, T W Harrison, and A E Tattersfield Time course of action of two inhaled corticosteroids, fluticasone propionate and budesonide Thorax, January 1, 2004; 59(1): 26 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rohatagi, S. Appajosyula, H. Derendorf, S. Szefler, R. Nave, K. Zech, and D. Banerji Risk-Benefit Value of Inhaled Glucocorticoids: A Pharmacokinetic/Pharmacodynamic Perspective J. Clin. Pharmacol., January 1, 2004; 44(1): 37 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Agertoft and S. Pedersen Lung Deposition and Systemic Availability of Fluticasone Diskus and Budesonide Turbuhaler in Children Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 779 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. Lynd, D. P. Guh, P. D. Pare, and A. H. Anis Patterns of Inhaled Asthma Medication Use: A 3-Year Longitudinal Analysis of Prescription Claims Data From British Columbia, Canada Chest, December 1, 2002; 122(6): 1973 - 1981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. PEDERSEN Do Inhaled Corticosteroids Inhibit Growth in Children? Am. J. Respir. Crit. Care Med., August 15, 2001; 164(4): 521 - 535. [Full Text] [PDF]
|
|
|
|
|
|
S.H. Korn, A. Jerre, and R. Brattsand Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells Eur. Respir. J., June 1, 2001; 17(6): 1070 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Chanez, R. Karlstrom, and P. Godard High or standard initial dose of budesonide to control mild-to-moderate asthma? Eur. Respir. J., May 1, 2001; 17(5): 856 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Lipworth and R. C. de Mooij Relative Effects of Exogenous Inhaled Corticosteroids on Diurnal Cortisol Secretion Arch Intern Med, September 11, 2000; 160(16): 2549 - 2550. [Full Text]
|
|
|
|
 |
|
 Inhaler devices for asthma DTB, February 1, 2000; 38(2): 9 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Inhalation devices and propellants Can. Med. Assoc. J., November 1, 1999; 161(90111): s44 - 50. [Full Text]
|
|
|
|
|
|
A. Pietinalho, P. Tukiainen, T. Haahtela, T. Persson, and O. Selroos Oral Prednisolone Followed by Inhaled Budesonide in Newly Diagnosed Pulmonary Sarcoidosis: A Double-Blind, Placebo-Controlled Multicenter Study Chest, August 1, 1999; 116(2): 424 - 431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. DEROM, J. VAN SCHOOR, W. VERHAEGHE, W. VINCKEN, and R. PAUWELS Systemic Effects of Inhaled Fluticasone Propionate and Budesonide in Adult Patients with Asthma Am. J. Respir. Crit. Care Med., July 1, 1999; 160(1): 157 - 161. [Abstract] [Full Text]
|
|
|
|
|
|
A. MELLEN, P. ARVIDSSON, M. PALMQVIST, and J. LOTVALL Equivalent Bronchodilation with Salbutamol Given via pMDI or Turbuhaler Am. J. Respir. Crit. Care Med., May 1, 1999; 159(5): 1663 - 1665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Aziz and B. J. Lipworth A Bolus of Inhaled Budesonide Rapidly Reverses Airway Subsensitivity and {beta}2-Adrenoceptor Down-regulation After Regular Inhaled Formoterol Chest, March 1, 1999; 115(3): 623 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Agertoft, A Andersen, E Weibull, and S Pedersen Systemic availability and pharmacokinetics of nebulised budesonide in preschool children Arch. Dis. Child., March 1, 1999; 80(3): 241 - 247. [Abstract] [Full Text]
|
|
|
|
|
|
J. W. Georgitis The 1997 Asthma Management Guidelines and Therapeutic Issues Relating to the Treatment of Asthma Chest, January 1, 1999; 115(1): 210 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. van der MOLEN, B. MEYBOOM-DE JONG, H. H. MULDER, and D. S. POSTMA Starting with a Higher Dose of Inhaled Corticosteroids in Primary Care Asthma Treatment Am. J. Respir. Crit. Care Med., July 1, 1998; 158(1): 121 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Donnelly, K. Williams, A. Baker, C. Badcock, R. Day, and J. Seale Effects of budesonide and fluticasone on 24-hour plasma cortisol. A dose-response study Am. J. Respir. Crit. Care Med., December 1, 1997; 156(6): 1746 - 1751. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. A. Pauwels, C.-G. Lofdahl, D. S. Postma, A. E. Tattersfield, P. O'Byrne, P. J. Barnes, A. Ullman, and The Formoterol and Corticosteroids Establishing Th Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma N. Engl. J. Med., November 13, 1997; 337(20): 1405 - 1411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. WILSON, L. C. MCFARLANE, and B. J. LIPWORTH Dose-response Effect for Adrenal Suppression with Repeated Twice Daily Inhaled Fluticasone Propionate and Triamcinolone Acetonide in Adult Asthmatics Am. J. Respir. Crit. Care Med., October 1, 1997; 156(4): 1274 - 1277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. THOMPSON Drug Delivery to the Small Airways Am. J. Respir. Crit. Care Med., May 1, 1997; 157(5): 199 - 202. [Full Text]
|
|
|
|
 |
|
 H. Bisgaard Drug delivery from inhaler devices BMJ, October 12, 1996; 313(7062): 895 - 896. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
